Hexvix (Hexaminolevulinate)

Hexvix is indicated for the detection of non‑muscle invasive bladder cancer during fluorescence‑guided cystoscopy. It assists urologists in identifying carcinoma in situ and other flat or papillary lesions that may be missed with white‑light examination.

• Enhances visualization of malignant urothelial tissue under blue light.
• Helps differentiate cancerous lesions from benign inflammation.
• Supports targeted biopsy of suspicious areas.
• May reduce the need for repeat cystoscopic procedures.
• Facilitates mapping of tumor extent for treatment planning.
• Provides real‑time feedback that can guide immediate therapeutic decisions.

• Hexaminolevulinate is preferentially taken up by urothelial cells and enters the heme biosynthetic pathway, where it is converted to protoporphyrin IX. Protoporphyrin IX accumulates preferentially in malignant cells and emits red fluorescence when excited by blue light (approximately 405 nm). This fluorescence contrast enables clinicians to distinguish cancerous tissue from normal urothelium during cystoscopic examination. The selective accumulation results from increased metabolic activity and altered porphyrin transport in tumor cells.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of hexaminolevulinate.

Common

• Transient bladder irritation, including burning or discomfort.
• Mild hematuria or pink urine discoloration.
• Urinary urgency or frequency lasting a few hours.
• Low‑grade fever or chills shortly after instillation.
• Temporary increase in urinary pain during the first 24 hours.

Serious

• Severe allergic reaction such as anaphylaxis.
• Persistent urinary retention requiring catheterization.
• Significant bladder wall inflammation (cystitis) with pain.
• Photosensitivity reactions in surrounding skin if exposed to strong light.
• Development of bladder ulceration requiring medical intervention.

Most events are mild and resolve without specific treatment, but patients should be monitored for any worsening symptoms.

Before using Hexvix, clinicians should evaluate patient history and bladder condition to minimize risks associated with the diagnostic procedure.

• Confirm no active urinary tract infection before instillation.
• Ensure the bladder is adequately emptied and then filled with the prescribed volume of solution.
• Avoid exposure of the bladder to strong external light sources for several hours after the procedure.
• Review any known hypersensitivity to porphyrin compounds or similar photosensitizers.
• Use caution in patients with severe renal impairment or those on dialysis.
• Defer use in pregnant or breastfeeding women until safety data are available.

Hexvix may interact with other agents or clinical conditions that affect photosensitivity or bladder physiology.

Avoid

• Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium) that could amplify fluorescence reactions.
• Direct exposure of the bladder to intense light sources (e.g., laser therapy) immediately after administration.
• Use of topical bladder irritants (e.g., antiseptic solutions) within 48 hours, which may interfere with fluorescence.

Use with caution

• Anticoagulant therapy, as minor bleeding may be more apparent during cystoscopy.
• Intravesical chemotherapy agents given within 24 hours, which could alter mucosal absorption.
• Patients with severe hepatic dysfunction, because altered porphyrin metabolism may increase systemic exposure.
• Patients taking photosensitizing antibiotics such as tetracyclines should be monitored for prolonged skin sensitivity.